Cytokinetics Inc (NASDAQ:CYTK) shares, rose in value on Thursday, March 06, with the stock price down by -1.39% to the previous day’s close as strong demand from buyers drove the stock to $43.27.
Actively observing the price movement in the last trading, the stock closed the session at $43.88. Referring to stock’s 52-week performance, its high was $75.71, and the low was $40.53. On the whole, CYTK has fluctuated by -12.05% over the past month.
With the market capitalization of Cytokinetics Inc currently standing at about $5.12 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 3.09M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CYTK’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CYTK currently trading nearly -4.34% and -7.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.82, while the 7-day volatility ratio is showing 7.10% which for the 30-day chart, stands at 6.49%. Furthermore, Cytokinetics Inc (CYTK)’s beta value is 0.90, and its average true range (ATR) is 2.67.
A comparison of Cytokinetics Inc (CYTK) with its peers suggests the former has fared considerably weaker in the market. CYTK showed an intraday change of -1.39% in last session, and over the past year, it shrunk by -36.07%%.
Data on historical trading for Cytokinetics Inc (NASDAQ:CYTK) indicates that the trading volumes over the past 3 months, they’ve averaged 1.47 million. According to company’s latest data on outstanding shares, there are 118.21 million shares outstanding.
Nearly 2.57% of Cytokinetics Inc’s shares belong to company insiders and institutional investors own 109.90% of the company’s shares. The stock has fallen by -8.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CYTK stock heading into the next quarter.
